CBD KANU 1:1

Best patient/client profiles

1. Adults with chronic neuropathic pain or mixed chronic pain
This is one of the most defensible categories. Evidence suggests THC/CBD combinations can provide small-to-moderate short-term improvement in neuropathic pain for some adults, especially when conventional options have not worked well. The 2021 meta-analysis found THC/CBD users were more likely to achieve at least 30% pain reduction than placebo, but the authors stressed the need for better trials and careful patient selection.

2. Patients with multiple sclerosis spasticity or muscle spasms
This is probably the strongest scientific comparison for a 1:1 cannabinoid product. NICE reviewed cannabis-based medicines for spasticity and concluded that THC:CBD spray could be offered as a 4-week trial for adults with moderate to severe MS spasticity when other treatments have not been effective.

3. Oncology supportive-care patients with refractory chemotherapy nausea/vomiting
ASCO’s 2024 cancer guideline says adults with cancer who still have nausea or vomiting despite standard antiemetic therapy may consider dronabinol, nabilone, or a quality-controlled oral 1:1 THC:CBD extract. It also clearly says cannabis/cannabinoids should not be used as a cancer-directed treatment or as a substitute for cancer treatment.

4. Adults with pain-related sleep disturbance
This is a reasonable secondary positioning: not “treats insomnia,” but may support nighttime comfort when pain or spasms interfere with sleep. The evidence for sleep is weaker than for MS spasticity and neuropathic pain, so the safest language is: “for adult patients whose prescriber is seeking balanced evening cannabinoid support.”

5. Experienced medical cannabis patients who need a predictable edible format
A gummy can be convenient and discreet, but oral THC takes longer to act. Health Canada warns that ingested cannabis can take up to 4 hours to feel full effects and may last 6–12 hours, so patients must avoid taking more too soon.

Who should avoid or use only with strong medical supervision

CBD KANU 1:1 Gummies

This concept is scientifically very strong because the formula is balanced THC + CBD, with the uploaded package showing 30 gummies and the 1:1 idea positioned around 10mg THC + 10mg CBD per gummy. Wow effect!

Why the 1:1 THC:CBD combination makes sense

A 1:1 formula is considered a balanced cannabinoid profile. THC is the stronger cannabinoid for analgesia, nausea control, appetite, sleep support and muscle relaxation, but it can also cause anxiety, dizziness, sedation or intoxication in sensitive patients. CBD is non-intoxicating and may help modulate some THC effects depending on dose, route and patient profile. Clinically, the best-known 1:1 medical product is nabiximols/Sativex, which delivers 2.7 mg THC + 2.5 mg CBD per spray; four sprays are very close to one CBD KANU gummy in total THC/CBD amount, although the route is different.

The strongest medical rationale is that THC and CBD together may offer broader symptom coverage than CBD alone, especially when the patient has pain, spasticity, nausea, poor sleep or appetite issues. A 2021 meta-analysis of 17 randomized trials in neuropathic pain found that THC/CBD products significantly reduced pain intensity compared with placebo, although the evidence quality was moderate-to-low and side effects remain important.

CBD KANU 1:1 Oil

Not ideal for children/adolescents, pregnancy or breastfeeding, patients with psychosis/bipolar instability, history of substance-use disorder, uncontrolled cardiovascular disease, high fall risk, or people who must drive/work with machinery. THC products can cause dizziness, sedation, confusion, anxiety, paranoia, tachycardia and dependence risk, especially with higher doses or frequent use.

Page updated

Google Sites

Report abuse